Allegro Diagnostics is your global leader in the diagnosis of epithelial diseases by providing earlier, more accurate information to clinicians and patients about patient health.

Allegro Diagnostics to Present at AdvaMed 2011

Maynard, MA, September 23, 2011. Allegro Diagnostics today announced its participation in the AdvaMed 2011 conference, being held September 26-28 in Washington, D.C. Michael D. Webb, President and CEO, will present on Tuesday, September 27 at 9:10AM ET in room 204A of the Walter E. Washington Convention Center. Mr. Webb will provide an overview of Allegro’s molecular testing platform for the early detection of lung cancer, as well as its lead genomic test, BronchoGen™.

About the Allegro Platform

Allegro Diagnostics' molecular testing platform utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. The "field of injury" principle on which the platform is based refers to the common molecular response that occurs throughout the respiratory tract in current and former smokers with lung cancer. These changes can be detected in a gene expression signature from non-malignant airway cells and indicate the presence of malignancy remotely in the lung. Allegro has applied this platform to generate multiple product candidates.

About Allegro Diagnostics

Allegro Diagnostics is a molecular diagnostics company focused on the development and commercialization of innovative genomic tests for the diagnosis, staging and informed treatment of lung cancer and other lung diseases. Allegro has developed a molecular testing platform that utilizes a genomic biomarker to detect early signs of lung cancer in current and former smokers. The company’s lead product is the BronchoGen™ genomic test for use in combination with standard bronchoscopy for the early diagnosis of lung cancer.

Contact:

Jennifer Conrad
MacDougall Biomedical Communications
jconrad@macbiocom.com
(781) 235-3060